For at least the last nine years, I have been advising clients against any 5 alpha reductase drug. My opposition to such drugs was based on the latest study on Finasteride which I detail below. Over the years, further information has emerged which I also detail.
In the case of Avodart I was making an assumption that even though it is a different drug it is also a 5 alpha reductase drug and therefore was likely to have similar side effects and consequences.
Finasteride has downsides. A Norris Cancer Institute study on Finasteride in 1999 found that while it reduced the incidence of prostate cancer by 25% it also increased the incidence of the virluent fatal form of prostate cancer by 300%.
In fact a recent article in the UK’s Daily Telegraph newspaper has detailed a study showing that Finasteride also increases your risk of getting male breast cancer. The manufacturer is going to have to put a warning on the label in the UK.
Finasteride is a feminizing drug. As a result it reduces ejaculate. It depresses libido and can cause problems with sexual function including erectile dysfunction. The same goes for Avodart.
Everything has to be put in the context that there is a perfectly good, in fact better and healthier solution for an enlarged prostate. Why take a toxic and dangerous drug that has unfortunate side effects, when diet, exercise and my supplement total health is safe, healthy, and effective?
Recently a new study on Avodart was published in the New England Medical Journal. GlaxoSmithKline, which manufacturers Avodart, paid for the study; Andriole received consulting and lecture fees from GlaxoSmithKline and other drug companies.
GSK is seeking approval for Avodart from the Food and Drug Administration to be used as a cancer preventive for men at higher-than-normal risk of the disease. The drug is already sold for urinary problems and I have opposed its use for that. Such a new approval could open a large lucrative market for them, but probably cause harm to their customers.
What is interesting is that my assumption that Avogart would have exactly the same problems as Finasteride has been borne out by this new study.
After four years, there were 659 prostate cancers among the 3,305 men on Avodart, compared with 858 cancers among the 3,424 men on a placebo. Thus, Avodart cut cancer risk 23 percent — about the same as in the finasteride study.
But a more complex picture emerges from data on the aggressiveness of the cancers — indicated by a “Gleason score” — and when the tumors were detected by biopsy.
Compared with the placebo group, the Avodart group had far fewer non-aggressive cancers, roughly the same number of somewhat-aggressive cancers, but a significantly greater number of extremely aggressive “high- grade” cancers — the kind that are often fatal.
Over four years, Avodart takers were diagnosed with 29 high-grade cancers, compared with 19 for men on a placebo. The disparity surfaced in the third and fourth years, when men on Avodart had 12 high-grade tumors, while the placebo group had only one.
American Cancer Society Director of Prostate and Colorectal Cancers Durado Brooks, MD, admitted to WebMD in an interview. “We now have two studies showing that two different drugs in this category can reduce the overall risk of prostate cancer, But we don’t have studies saying that they decrease the risk of death from prostate cancer.”
That of course is the nub of the problem with all the toxic drugs and invasive treatments which conventional medicine uses to treat prostate disease and cancer. The pharmaceutical corporations certainly like to measure things like PSA, Gleason and the size of a tumor but what they really hate to do is look at eventual outcomes. The reason for that of course, is that the eventual outcome never seems to be beneficial. Independent researchers however, need to look at eventual outcomes.
Here is an excerpt from the latest study by Researchers at the Institute for Clinical and Economic Review, which is based at the Massachusetts General Hospital’s Institute for Technology Assessment published by the National cancer institute on their website January 12th.
They concluded that the various approaches—including active surveillance, surgery, and radiation therapy—result in similar overall survival and tumor recurrence rates. However, compared with the immediate treatment options, active surveillance yields both a comparable net health benefit and more quality- adjusted life years for men age 65 and older, according to the economic model used in this study.
So back to the study on Avodart, the study also found a higher rate of cardiac failure in men taking dutasteride (Avodart) – 0.7 percent vs. 0.4 percent for those taking the placebo.
So not only do you have to suffer unfortunate side effects if you take Avodart, but you also have a greater chance of getting a fatal form of prostate cancer and a greater chance of suffering a fatal heart attack.
If you are currently taking either Proscar (Finasteride) or a Avodart (Dutasteride) please consider trying a natural and holistic method to achieve better and safer results.
I highly recommend that you read my guide “All about the Prostate” to know more how to deal with your prostate disease naturally.
I wish you good health,
Ben Ong
Share and Help a Friend Improve One's Health: